Editas Medicine (EDIT) Announces $125M Offering of Common Stock

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additional $18.8 million of shares of its common stock. All of the shares in the offering are to be sold by Editas Medicine.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

You May Also Be Interested In

• Delivery Hero boards recommend Uber's €41.50-per-share takeover offer
• TD Cowen on O'Reilly Automotive (ORLY): 'Leading Execution On Full Display At Our #1 Idea'
• Editas Medicine to Participate in Upcoming Investor Conferences